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Abstract
Cardiomyopathy or disease of the heart muscle involves abnormal enlargement 
and a thickened, stiff, or spongy-like appearance of the myocardium. As a result, 
the function of the myocardium is weakened and does not sufficiently pump blood 
throughout the body nor maintain a normal pumping rhythm, leading to heart failure. 
The main types of cardiomyopathies include dilated hypertrophic, restrictive, 
arrhythmogenic, and noncompaction cardiomyopathy. Abnormal trabeculations of 
the myocardium in the left ventricle are classified as left ventricular noncompaction 
cardiomyopathy (LVNC). Myocardial noncompaction most frequently is observed 
at the apex of the left ventricle and can be associated with chamber dilation or 
muscle hypertrophy, systolic or diastolic dysfunction, or both, or various forms of 
congenital heart disease. Animal models are incredibly important for uncovering 
the etiology and pathogenesis involved in this disease. This chapter will describe 
the clinical and pathological features of LVNC in humans and present the animal 
models that have been used for the study of the genetic basis and pathogenesis of 
this disease.
Keywords: animal models, noncompaction, cardiomyopathy, mutation,  
cardiac development
1. Introduction
Left ventricular noncompaction (LVNC) is a unique form of cardiomyopathy 
that is distinguished by a distinctive (“spongy”) morphological appearance of the 
left ventricle (LV) myocardium [1]. This “spongy” appearance encompasses hyper-
trabeculation, deep intertrabecular recesses or sinusoids, and a bilayered ventricular 
myocardium with a noncompacted endocardium and compacted epicardium [2]. 
Although LVNC is rare, the prevalence of LVNC is reported to be <0.3% in adults 
and < 0.0001% in children. It is the third most common form of inherited cardiomy-
opathies and accounts for 9% of all pediatric cardiomyopathy cases [3]. Prevalence 
was reported as 0.014–1.3% in adult patients who underwent echocardiography. 
In heart failure patients, the prevalence of LVNC is estimated at 3–4% [4]. LVNC 
is characterized as genetic, primary cardiomyopathy by the 2006 American Heart 
Association classification model, whereas the European Society of Cardiology has not 
classified LVNC as distinct cardiomyopathy due to its phenotypic heterogeneity [5, 6].
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Clinical presentation of LVNC is variable, and Towbin et al. have described nine 
distinct subtypes: 1) benign, 2) arrhythmogenic, 3) dilated, 4) hypertrophic, 5) mixed 
hypertrophic and dilated, 6) restrictive, 7) right ventricular with the normal left 
ventricle, 8) biventricular, and 9) associated with congenital heart disease [7]. Some of 
the LVNC phenotypes are shown in Figure 1. Complications of LVNC include chronic 
heart failure, arrhythmias, cardioembolism, chest pain, dyspnea, syncope, myocardial 
infarction, and sudden cardiac death (SCD) [8]. Patients with LVNC associated with 
neuromuscular disease may present with exercise intolerance, fatigue, muscle pain, 
muscle stiffness, and muscle weakness. Heart failure associated with LVNC is often 
due to either systolic or diastolic ventricular dysfunction. Electrocardiogram (ECG) 
abnormalities are very common (88–94% and 88%, respectively) in both adult and 
pediatric cases. Common arrhythmias are atrial fibrillation, atrial flutter, paroxysmal 
supraventricular tachycardia, and atrioventricular block. Heart failure and arrhyth-
mias are the greatest cause of concern for mortality in LVNC patients [9].
Figure 1. 
Echocardiographic images of heterogeneous forms of left ventricular noncompaction phenotype. A. Parasternal 
short-axis view of a dilated form of LVNC with trabeculations noted at the apex. B. An apical 4-chamber 
view with trabeculations noted at the right side of the image. C-G, Heterogeneous phenotypes associated with 
LVNC. LVNC with normal LV size, thickness, and function (C), dilated form of LVNC (D), hypertrophic 
form of LVNC (E), restrictive form of LVNC (F), biventricular LVNC (G). LV, left ventricle; RV, right 
ventricle; LA, left atrium, RA, right atrium.
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The etiology, pathogenesis, and natural history of LVNC are not clearly under-
stood. The genetic causes of LVNC are heterogeneous [10, 11], involving final common 
pathways initiated by primary (the sarcomere) and developmental (NOTCH pathway) 
genetic abnormalities, often via a disturbance of protein–protein binding caused 
by the primary genetic mutation [12]. Doppler echocardiography, cardiac magnetic 
resonance imaging, or LV angiography are used for the diagnosis. Due to heritable 
nature, patients with LVNC and at-risk first-degree relatives are recommended to 
undergo genetic screening and counseling [13, 14]. Clinical symptoms associated with 
myocardial dysfunction, significant arrhythmias, congenital heart disease, or neuro-
muscular disease combined with the results of genetic testing dictate the outcome and 
therapeutic management of LVNC [15]. Family studies and animal models are incred-
ibly important for uncovering the genetic basis and pathways involved in this disease. 
In this chapter, we describe trabeculation and compaction events during cardiogenesis, 
morphopathological features of LVNC, and possible genetic mechanisms of LVNC. We 
will also describe the animal models that have been used for the study of LVNC.
2. Embryonic development of compacted myocardium
The underlying mechanisms for LVNC remain largely unknown, but many 
studies associate it with the failure of compaction of trabecular myocardium during 
embryogenesis [16]. The development of the functionally competent, compacted, and 
multilayered myocardial wall is a two-part process consisting of trabeculation fol-
lowed by a compaction process set at the midgestational period of cardiogenesis [17]. 
When the myocardial spiral system enfolds, myocyte recruitment and proliferation 
lead to myocardial maturation with the development of protrusions into the lumen. 
Endocardial cells invaginate, and cardiomyocytes in specific regions along the inner 
wall of the heart form sheet-like protrusions into the lumen to give rise to the trabecu-
lar myocardium [16]. The intertrabecular recesses communicate with the blood-filled 
cavity of the heart tube to increase the surface area for gas exchange and blood. This 
mechanism favors the concomitant increase in myocardial mass despite the absence of 
a distinct epicardial coronary circulation [18].
The trabecular myocardium starts undergoing compaction between weeks 5 and 8 
of human embryonic development and coincides with the invasion of the developing 
coronary vasculature from the epicardium. Compaction is gradual, from the epicardial 
to the endocardial surface and from the basal segments of the ventricle moving toward 
the apex [19]. Vascular endothelial growth factor (VEGF) and angiopoietin-1 may be 
involved with triggering compaction [2]. As a result of the compaction process, the 
intertrabecular recesses disappear almost entirely leaving a smooth endocardial ven-
tricular surface. Compaction is more pronounced in the LV than in the right ventricle 
(RV), therefore the RV endomyocardial surface is more heavily trabeculated (Figure 2)  
[19]. On the other hand, noncompaction indicates failure of compact myocardium 
formation, leaving spongy myocardium and deep intertrabecular recesses [20].
2.1 Etiopathophysiology of LVNC and genotype: phenotype correlation
While the etiology of LVNC is not clearly understood, it is largely considered 
that hypertrabeculation or noncompaction in LVNC has a genetic origin with typi-
cally autosomal dominant inheritance if the implicated genes encode components 
of the sarcomere, Z-disc, or cytoskeleton [21]. Autosomal recessive, X-linked, 
and mitochondrial inheritance patterns have also been found [3, 22]. One large 
retrospective multicenter study showed that nearly one-third of the LVNC patients 
had genetic variants in at least one cardiomyopathy-causative gene [14]. LVNC 
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has also been reported in many complex syndromes [23, 24] and neuromuscular 
disorders [25–27]. LVNC can also be considered congenital or acquired, and several 
hypotheses have been proposed for the development of LVNC [28]. The primary 
hypothesis for congenital LVNC is the embryonic hypothesis, which attributes the 
hypertrabeculation of LVNC to the arrest in normal ventricular compaction during 
myocardial embryogenesis [29]. The etiology of LVNC can be described as having 
two components, congenital and modifier factors.
Genetically, LVNC is heterogeneous and has been associated with chromosomal 
defects and genetic mutations in myosin heavy chain 7 (MYH7) [21, 30], LIM 
domain-binding protein 3 (ZASP), α-dystrobrevin (DTNA), tafazzin (TAZ/G4.5), 
ion channels, and proteins found in the sarcomere, cytoskeleton, and mitochondria. 
Alterations in the NOTCH signaling pathway, associated with morphological develop-
ment, and WNT pathway signaling, embryonically involved in body axis patterning 
and cell polarity, are also linked to LVNC [20, 31]. In some categories of LVNC, the 
genotype–phenotype correlation is identifiable. Tafazzin mutations, one of the first 
mutations linked to LVNC, are characteristic of Barth syndrome, an X-linked genetic 
disorder that commonly presents with LVNC. Tafazzin, an inner mitochondrial mem-
brane protein, catalyzes phospholipid cardiolipin synthesis, which is essential for 
mitochondrial integrity and energy production in cardiomyocytes [29, 32]. Family 
studies have identified mutations in hyperpolarization-activated cyclic nucleotide-
gated channel 4 (HCN4), sodium voltage-gated channel alpha subunit 5 (SCN5A), and 
ankyrin 2 (ANK2) as genetic abnormalities underlying sinus bradycardia-associated 
LVNC [33]. Lamin A/C (LMNA) mutations, which are also found in dilated cardiomy-
opathies, are associated with the early onset of advanced atrioventricular block [34]. 
A 6.8-megabase locus on chromosome 11p15, containing muscle LIM protein (MLP/
CSRP3) and SOX6, was implicated in an autosomal dominant pedigree of LVNC [35]. 
The V470I variant in bone morphogenetic protein 10 (BMP10) and W143X variant 
in neuregulin (NRG1) were identified in two unrelated LVNC probands and their 
affected family members [36]. Impaired BMP receptor binding ability, perturbed 
proliferation and differentiation processes, and intolerance to stretch in mutant cardio-
myoblasts may underlie myocardial noncompaction in these families.
Figure 2. 
Gross morphopathologic appearance of LVNC. a. Heart from a individual with left ventricular 
noncompaction. Note the spongy appearance of the ventricular wall, caused by ‘holes’ in the myocardium, 
which represent deep trabeculations. The heart is thick and has a dilated chamber (that is, hypertrophic and 
dilated). In life this ventricle functioned poorly. LV, left ventricle; LVNC, trabeculations of left ventricular 
noncompaction. b. Numerous excessive prominent trabeculations and deep intertrabecular recesses is noted by 
arrows. The trabecular zone (noncompacted layer, X) in the LV is at least twice thick as the compact layer (Y) 
of the ventricular wall. (Adopted from Towbin and Bowles, Nature 415, 227–233. 2002).
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The causal nature of genetic defects is further complicated by the overlap of 
genetic mutations in distinct cardiomyopathies. LVNC can be categorized based on 
its association with dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy 
(HCM), and other forms of heart muscle disease. Using next-generation sequenc-
ing, several groups revealed a wide range of pathogenic variants in LVNC patients 
and an association between pathogenic variants and poor prognoses, especially in 
those patients harboring multiple pathogenic variants [10, 11, 37, 38]. Variants in 
MYH7 were associated with HCM, DCM, and restrictive cardiomyopathy (RCM). 
Patients with sarcomeric genes variants had more frequent findings of trabecula-
tions and likelihood fibrosis in the interventricular septum of the myocardium [11]. 
Variants in mindbomb homolog 1 (MIB1), LMNA, and MLP were linked to LVNC 
associated with DCM. Myosin-binding protein C (MYBPC3) mutations are associ-
ated with LVNC-hypertrophic cardiomyopathy, while SCN5A and DSP variants are 
reported causative for arrhythmogenic cardiomyopathy (ACM), DCM, and cardiac 
conduction system dysfunction disorders including Brugada syndrome and long QT 
syndrome. Interestingly, truncating variants in the LAMP2 gene that is causative for 
Danon disease were identified in LVNC patients by Li et.al [37]. In addition, mito-
chondrial genome mutations [39], chromosomal abnormalities such as 1p36 dele-
tion, 7p14·3p14·1 deletion, 18p subtelomeric deletion, 22q11·2 deletion, distal 22q11·2, 
8p23·1 deletion trisomies 18 and 13, and tetrasomy 5q35·2–5q35 have been associated 
with syndromic LVNC [40–44]. Patients with Coffin–Lowry syndrome (RPS6KA3 
mutation), Sotos syndrome (NSD1 mutation), and Charcot–Marie–Tooth disease 
type 1A (PMP22 duplication) have also been reported to manifest clinical signs of 
LVNC [23, 45–47]. Titin encoded by the TTN gene with 364 exons is the largest 
protein, expressed in striated muscles [48]. A missense variant TTN A178D identi-
fied by high throughput next-generation whole-genome sequencing techniques that 
have been implicated in clinical genetics practice over the last decade has recently 
been associated with autosomal dominant LVNC and DCM [49]. Nonetheless, a 
genotype–phenotype correlation may not be identifiable for all mutations and vari-
ants. Genetic defects may have incomplete penetrance and variable expressivity or 
have no causal relationship between genotype and phenotype [2].
The embryonic hypothesis does not explain acquired LVNC that presents after 
birth, some forms of which are potentially reversible. Acquired LVNC, has been 
identified in athletes, pregnant women, and patients with sickle cell anemia, 
myopathies, and chronic renal failure [50]. The etiology of acquired LVNC is merely 
speculative. One such hypothesis argues that mild LVNC can remain undetected 
until transient LV dilation allows LVNC to become visible under precise and accurate 
imaging [51]. It is also speculated that acquired LVNC may be due to cardiac remod-
eling from increased preload and altered hemodynamics [29]. Ventricular trabecula-
tion in athletes, particularly in the LV apex, allows for increased compliance which 
reduces wall stress and strain [52]. Given the high risk of possible cardiac embolic 
events from thrombus formation in the intertrabecular recesses, clinical trials for 
thromboembolic events in isolated LVNC have been suggested [53–55].
2.2 Diagnosis and therapeutic strategy
The clinical manifestations of LVNC vary widely, including no symptoms, 
thromboembolic events (ventricular or systemic arterial), LV dilation, impaired 
contractility with heart failure leading to pulmonary edema, arrhythmia including 
ventricular tachycardia and atrial fibrillation, and sudden cardiac death. Patients 
with neuromuscular disorder and LVNC may present with elevation in muscle 
form of creatine kinase, CK-MM (creatine kinase, muscle isoform) consistent with 
skeletal myopathy [7].
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Echocardiography is the first-line diagnostic routine and an accessible technique 
to detect abnormal trabeculations or a “spongy” appearance of the myocardium. 
Several diagnostic criteria have been developed to define LVNC through echocar-
diographic analysis. A ratio of >2:1 in thickness of noncompacted to compacted 
layers during diastole is deemed diagnostic for LVNC [56, 57]. Compared with 
echocardiography, cardiac magnetic resonance (CMR) imaging offers more in-
depth anatomic and functional features of the noncompacted myocardium. Late 
gadolinium enhancement specifically provides detection of cardiac fibrosis. CMR 
criteria developed by Petersen et al. to accurately diagnose pathologic noncompac-
tion is based on a noncompaction to compaction ratio at end-diastole of >2.3 [58]. 
Quantitative CMR criteria by Jacquier et al. define LV noncompacted mass > 20% 
of the total mass for accurate LVNC diagnosis [59], while Grothoff et al. propose 
LV mass > 25% of the total mass as well as a noncompacted mass > 15 g/m2 [60]. 
Despite all these proposed criteria, there are wide inconsistencies and poor specific-
ity, and it remains difficult to accurately differentiate normal variants in trabecula-
tions from pathological LVNC [61]. Therefore, data matrices 0f echocardiography 
and CMR imaging measurements, electrocardiogram features, and clinical genetics 
of the patient and relatives are helpful for confirming the clinical diagnosis [7].
Genetic testing in patients with LVNC and family members has been important 
in identifying genetic causes of cardiac dysfunction. Testing can be done on genes 
known to be associated with LVNC and other forms of cardiomyopathy as well as 
genes involved in syndromic diseases such as metabolic abnormalities, mitochon-
drial dysfunction, Barth syndrome, and storage diseases. Identification of patho-
genic variants in probands and family members can be followed by segregation 
studies in the family [15].
Treatment strategy in LVNC depends on clinical presentations and complica-
tions, and clinical needs are managed according to corresponding guidelines [62]. 
The key targets of clinical management are the treatment of heart failure (including 
beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor 
blockers, aldosterone antagonists, diuretics, and heart transplantation), arrhyth-
mias (including ablation and implantation of an implantable cardioverter-defibril-
lator in patients with life-threatening events), and oral anticoagulation. In patients 
with congenital heart disease and LVNC, surgery for the congenital abnormalities 
takes precedence when feasible. In many cases, palliative surgery ultimately fails 
because of the myocardial abnormality, and cardiac transplantation is required [63].
3. Animal models of LVNC
LVNC is an overlap disorder and it appears that any of these “final common 
pathways” can be involved depending on the specific form of LVNC [64]. Combining 
information about disease-causing genes with murine models is crucial in identify-
ing pathways involved in ventricular noncompaction. For instance, Barth syndrome 
is caused by tafazzin mutations, and tafazzin knockdown mice were engineered 
using a short-hairpin RNA-inducible transgenic approach. These mice demonstrated 
hypertrabeculation and noncompaction, and the knockdown mice died prenatally at 
E12.5–14.5 [65]. New powerful cutting-edge gene-editing technologies using tran-
scription activator-like effector nucleases (TALENs) and clustered regularly inter-
spaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) have 
been used for modeling LVNC [66–69]. Patient-specific induced pluripotent stem 
cells (iPSCs) derived cardiomyocytes have emerged as a useful tool for investigating 
pathological mechanisms of many cardiovascular diseases including LVNC [70, 71]. 
Several signaling pathways such as the Dll4-NOTCH [72], MIB1 [73], BMP [74], and 
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TGF-β [71] have been demonstrated to regulate myocardial trabecular compaction as 
well as to be involved in the development of LVNC. While zebrafish and Drosophila 
have been used to study LVNC in addition to patient-specific iPSCs derived cardio-
myocytes, mice are more commonly used to genetically engineer LVNC phenotypes as 
shown in Table 1 [75, 76].
3.1 Animal models related to the Notch signaling pathway
The Notch signaling pathway is a highly conserved intercellular pathway involved 
with multisystem differentiation. Particularly in the cardiovascular system, Notch1 
mediates ventricular morphogenesis, coronary vessel development, and communica-
tion between the endocardium and myocardium for cardiomyocyte proliferation and 
differentiation. Mutations in the Notch signaling pathway cause congenital heart 
disease [77]. Mammals have Notch 1–4, a group of transmembrane receptors with an 
extracellular domain and an intracellular domain. The Notch extracellular domain 
(NECD) interacts with ligands of the Delta and Jagged family, and these receptor-
ligand interactions are modulated by manic fringe (Mfng) glycosyltransferase. Delta 
and Jagged ligands are ubiquitinated by Mib1, an E3 ubiquitin ligase, and trigger 
endocytosis of the ligand. Mib1 activity exposes the receptor to ADAM metallo-
proteases for Notch cleavage. In response, the Notch intracellular domain (NICD) 
translocates to the nucleus and acts as a transcription factor. The NICD is comprised 
of the RBPJ domain and ANK repeats [77].
The first murine model for LVNC was the Fkbp1a (or FKBP12)-deficient 
mouse. Deficiency in FKBP1a, a binding protein of the immunophilin family, 
causes ventricular noncompaction, thin ventricular walls, hypertrabecula-
tion, and ventricular septal defects [20, 78]. Fkbp1a is a negative modulator of 
activated Notch 1. In Fkbp1a-deficient mice, activated Notch1 is upregulated. 
In Fkb1a-deficient mice, Fkbp1a overexpression significantly reduced activated 
Gene Animal model Signaling Ref #
FKBP12 KO mouse Decrease in Notch1 activity, increase in BMP10 [79]
BMP10 KO E9.0–13.5 mouse TGF-b [80]
BMP10 Overexpression adult mouse TGF-b [81]
NUMB/NUMBL Double KO mouse Inhibition of Notch1, Smad6 and Smad7, WNT [82]
SMAD7 Mutant mouse BMP10, TGF-b [86]
TBX20 Overexpression mouse T-box family, TBX1 [87]
MIB1 Mutant zebrafish Reduces Notch1 [89]
MIB1 Decifient zebrafish Reduces Notch1 [89]
VEGF Overexpression mouse Notch1, Flk-1 [90]
Daam1 Decifient mouse PCP and WNT [92]
NKX2–5 KO mouse MEF2, HAND1, HAND2, GATA, BMP10 [96]
NFATC1 Mutant mouse NFAT [99]
TAZ Inducible knockdown Cardiolipin remodeling [102]
TAZ KO mouse Cardiolipin remodeling [65]
TTN Mutant mouse Telethonin loss [104]
Table 1. 
Animal models of LVNC.
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Notch1 [79]. Fkbp1a deficiency upregulates BMP10, a peptide growth factor in the 
TGF-β family involved in the cardiac compaction process. BMP10 upregulation in 
Fkbp1a-deficient mice indicates the importance of this gene in the trabeculation 
and compaction process.
In mouse embryogenesis, Bmp10 is transiently expressed in ventricular myocar-
dium at E9.0–13.5 during myocardial maturation and in the atria E16.5–18.5 [74]. 
BMP10-deficient mice embryos appear unaffected at E8.5–9.0, arrest at E9.0–9.5, 
and die at E10.5. Immunostaining of mutant embryos exhibited thin ventricular 
walls and primitive trabecular ridges. The localization of BMP10 to the ventricular 
myocardium for the brief period at E9.0–13.5 suggests that BMP10 is crucial for 
continued myocardial development. Postnatal cardiac-specific BMP10 overexpres-
sion compromised cardiac growth, caused subaortic narrowing and concentric 
myocardial thickening [80]. Human atrial natriuretic factor (hANF) promoter can 
be used to overexpress BMP10 in mice. Overexpression of BMP10 demonstrated 
hypertrabeculation and severe heart failure [81]. Like in Fkbp1a-deficient mice and 
cardiac overexpression models, BMP10 is also upregulated in NUMB/NUMBL-
deficient mice (myocardial double-knockout mice) [82]. NUMB and NUMBL 
proteins of the NUMB family are cell fate determinants for hemopoietic stem cells, 
muscle satellite cells, cancer stem cells, and hemangioblast progenitor cell types and 
maintain the fate of neural stem cells as well as regulate their differentiation [83]. 
Both NUMB and NUMBL inhibit Notch1 signaling and are crucial for trabeculation, 
cardiomyocyte proliferation and differentiation, and trabecular thickness [84]. 
On the other hand, inhibitory intracellular transducers such as Smad6 and Smad7 
negatively regulate the BMP/ TGF-β signaling pathway [85]. Smad7 is expressed 
by endothelial cells in the major arteries in mice, and Smad7 deficiency causes 
increased Smad 1, 5, and 8 in the endocardial endothelium [81, 86]. Unsurprisingly, 
Smad7 mutant mice demonstrate ventricular noncompaction, thin ventricular 
walls, and ventricular septal defect. One of the key mediators of BMP10 signaling 
in ventricular myocardial development and maturation is TBX20, a member of the 
TBX1 subfamily of the T-box family transcription factors [87]. In murine embryos, 
Tbx20 can be detected in the cardiac precursor cells at E7·5 and the developing myo-
cardium and endocardium at E8·0 [88]. Cardiac-specific overexpression of TBX20 
results in severe DCM, ventricular hypertrabeculation, and abnormal muscular 
septum, consistent with the DCM type of LVNC [87].
Another Notch pathway element, Mib1, is associated with the LVNC pheno-
type of biventricular noncompaction with dilation and heart failure [20]. Genetic 
sequencing of 100 European patients revealed two autosomal dominant muta-
tions—V943F and R530X. Injection of Mib1-mutated mRNA, corresponding to the 
V943F and R530X mutations, into zebrafish embryos disrupts Notch signaling [89]. 
Inactivation of Mib1 reduces Notch1 signaling and myocardial arrest. Mutant Mib1 
mice produce an LVNC phenotype of immature trabeculae and noncompaction [89].
Vascular endothelial growth factor (VEGF) is produced by the myocardium and 
plays a role in endocardium-myocardium communication by binding to endocardial 
receptor Flk-1 [20]. Overexpression of VEGF-A in mice causes hypertrabeculation, 
abnormalities in cardiac morphology and coronary vessels, and embryonic lethality 
at E12.5–14.0 [90].
3.2 Animal models related to the WNT signaling pathway
The planar cell polarity (PCP) pathway is a β-catenin-independent Wnt pathway 
that was first studied in Drosophila. The PCP pathway plays a role in the epithelial 
orientation of hair and sensory bristles, apical-basolateral polarity, gastrulation, 
and neurulation [31, 91]. Disheveled-associated activator of morphogenesis I 
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(Daam1) is a mediator of the PCP pathway and a formin protein found in the 
plasma membrane and cytoplasmic vesicles. Daam1 is involved with cardiac mor-
phogenesis and is highly expressed in murine cardiac tissue. Daam1-deficient mice 
have been shown to cause an LVNC phenotype with ventricular noncompaction and 
the thin ventricular wall. It is likely that the abnormalities seen in Daam1-deficient 
mice are due to cytoskeletal dysfunction since Daam1 is involved with F-actin 
assembly and sarcomere organization. Interestingly, the absence of Daam1 does 
not alter BMP10 expression nor cardiomyocyte proliferation, which offers another 
pathogenic model of LVNC through disruption in myofibrillogenesis, cytoskeleton 
organization, and cardiomyocyte polarization [31, 92].
NUMB is also a component of the adherens junction by forming complexes 
with β-catenin to regulate cellular adhesion via Wnt signaling [82]. It also interacts 
with integrin-β subunits to regulate cell migration and promote their endocytosis 
for directional cell migration. Deletion of NUMB and NUMBL from mouse hearts 
results in LVNC with congenital heart disease with atrioventricular septal defects, 
truncus arteriosus, and double outlet right ventricle in vivo [82]. This model shows 
that NUMB family proteins regulate trabecular thickness by inhibiting Notch1 
signaling and control cardiac morphogenesis in a Notch1-independent manner.
3.3 Animal models related to other signaling pathways
NKX2–5, a cardiac homeobox gene, is a transcription factor that regulates heart 
development, working along with MEF2, HAND1, and HAND2 transcription fac-
tors to direct heart looping during early heart development [93]. Genetic variants in 
NKX2–5 are associated with progressive cardiomyopathy and conduction defects in 
humans [94, 95]. Ventricular-muscle-cell-restricted knockout of NKX2–5 in mice 
leads to progressive atrioventricular block with conduction system cell dropout 
and fibrosis [96]. LVNC is a prominent feature in neonatal mice, with progressive 
biventricular dilation and heart failure developing early. It directly activates MEF2 
to control cardiomyocyte differentiation and operates in a positive feedback loop 
with GATA transcription factors to regulate cardiomyocyte formation. A high-level 
BMP10 expression in the adult ventricular myocardium has been also observed.
The expression of early response genes in lymphocytes is regulated by NFAT 
transcription factors [97]. NFATC1 mutant mouse embryos have cardiac abnormali-
ties including myocardial developmental abnormalities, narrowing or occlusion of 
the ventricular outflow tract, defective septum morphogenesis, and underdevelop-
ment of valves [98, 99]. Ventricular hypertrophy and noncompaction with hyper-
trabeculation were seen in 40% of mutant mice, suggesting that NFAT signaling 
pathways are important for hypertrabeculation and noncompaction as well as the 
development of valves and the septum.
Barth syndrome is caused by mutations in the X-linked TAZ and is associated 
with LVNC and abnormal cardiolipin remodeling [12, 100]. Tafazzin catalyzes 
cardiolipin maturation reactions at the final stage of cardiolipin biosynthesis [101]. 
Inducible knockdown of TAZ (TAZKD) in murine models using short-hairpin RNA 
(shRNA) exhibited an adult-onset LVNC associated with abnormal cardiolipin 
profiles and mitochondrial structural abnormalities [102]. Knockout of TAZ at the 
embryonic stage leads to unique developmental cardiomyopathy characterized by 
ventricular myocardial hypertrabeculation and noncompaction and early lethality, 
suggesting that mitochondrial function is important for proper myocardial  
development [65].
Cytoskeletal and sarcomeric proteins encoding gene mutations have been shown 
to account for 20% or more of LVNC [7]. Truncating variants in TTN are well-
documented to cause skeletal myopathies and cardiomyopathies including LVNC  
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[48, 49, 103]. Homozygous mouse model carrying titin A178D mutation created by 
using CRISPR-Cas9 gene-editing displayed features of mild DCM, but not LVNC 
phenotype [104]. These mice showed complete loss of telethonin from the Z-disc 
and induction of a proteo-toxic response in the heart upon aging and adrener-
gic stress.
4. Conclusions
The pathogenesis of LVNC, a recently classified cardiomyopathy, remains largely 
unclear. With over 40 genes linked to LVNC, both genotype variation and pheno-
type variation are vast. Genetic testing in families and individuals with LVNC shas 
proved useful in identifying disease-causing variants. While the Notch signaling 
pathway is implicated in the pathogenesis of LVNC, there may be other pathways 
leading to congenital and acquired forms of LVNC. Identifying specific pathway 
elements is crucial for diagnosis and treatment. Modeling LVNC variants can help 
us to determine the genetic basis and pathogenesis of the disease.
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